Shire rejects US$63 billion Takeda bid as Allergan drops pursuit


Japan's Takeda Pharmaceutical is in negotiations with Shire after making a third takeover bid worth around US$61 billion that was rejected by the London-listed rare diseases drugmaker. FILE PHOTO: Takeda Pharmaceutical's signboard is seen on its headquarters building in Tokyo, Japan January 30, 2018.



from Biotech News